NewsCatch up with our latest news, events and press Press Release James Cotton 29/08/2023 Press Release James Cotton 29/08/2023 Sentinel Oncology Limited announce first dose in phase 1 cancer trial for SOL578 Read More Event James Cotton 24/01/2023 Event James Cotton 24/01/2023 Sentinel Oncology present at the DDR Inhibitor Summit conference Read More Press Release James Cotton 26/09/2022 Press Release James Cotton 26/09/2022 Sentinel Oncology Ltd Sign Exclusive Worldwide License Agreement with PharmaEngine, Inc for the Rights to Develop and Commercialise SOL578, a Small Molecule Chk1 Inhibitor Read More Event James Cotton 08/07/2022 Event James Cotton 08/07/2022 Sentinel Oncology present at the ‘Fragile X Syndrome: Innovative Approaches to Finding a Cure’ event Read More Press Release James Cotton 02/09/2021 Press Release James Cotton 02/09/2021 Sentinel Oncology enters agreement to develop new fragile X therapy Read More Press Release James Cotton 26/11/2020 Press Release James Cotton 26/11/2020 Sentinel Oncology enters exclusive collaboration with PharmaEngine Inc for SOL578 Read More Press Release James Cotton 04/11/2019 Press Release James Cotton 04/11/2019 Sentinel Oncology and Phoremost extend collaboration Read More Press Release James Cotton 01/05/2018 Press Release James Cotton 01/05/2018 Sentinel Oncology receives Innovate UK grant to develop new drugs for the treatment of glioblastoma multiforme Read More Press Release James Cotton 18/07/2017 Press Release James Cotton 18/07/2017 Sentinel Oncology receive Innovate UK grant to study feasibility of drug in the treatment of Alzheimer's disease Read More Press Release James Cotton 02/05/2016 Press Release James Cotton 02/05/2016 Sentinel Oncology and NMI TT Pharmaservices awarded Eurostars grant for development of a novel biomarker for the treatment of Fragile X Syndrome Read More Press Release James Cotton 25/03/2015 Press Release James Cotton 25/03/2015 Sentinel Oncology announce recent grant award from Innovate UK Read More Press Release James Cotton 22/04/2014 Press Release James Cotton 22/04/2014 Sentinel Oncology and Oncothyreon Collaborate to Develop and Commercialise Small Molecule Chk1 Inhibitors Read More Older Posts Discover our cutting-edge scientific pipeline for cancer therapies Our pipeline
Press Release James Cotton 29/08/2023 Press Release James Cotton 29/08/2023 Sentinel Oncology Limited announce first dose in phase 1 cancer trial for SOL578 Read More
Event James Cotton 24/01/2023 Event James Cotton 24/01/2023 Sentinel Oncology present at the DDR Inhibitor Summit conference Read More
Press Release James Cotton 26/09/2022 Press Release James Cotton 26/09/2022 Sentinel Oncology Ltd Sign Exclusive Worldwide License Agreement with PharmaEngine, Inc for the Rights to Develop and Commercialise SOL578, a Small Molecule Chk1 Inhibitor Read More
Event James Cotton 08/07/2022 Event James Cotton 08/07/2022 Sentinel Oncology present at the ‘Fragile X Syndrome: Innovative Approaches to Finding a Cure’ event Read More
Press Release James Cotton 02/09/2021 Press Release James Cotton 02/09/2021 Sentinel Oncology enters agreement to develop new fragile X therapy Read More
Press Release James Cotton 26/11/2020 Press Release James Cotton 26/11/2020 Sentinel Oncology enters exclusive collaboration with PharmaEngine Inc for SOL578 Read More
Press Release James Cotton 04/11/2019 Press Release James Cotton 04/11/2019 Sentinel Oncology and Phoremost extend collaboration Read More
Press Release James Cotton 01/05/2018 Press Release James Cotton 01/05/2018 Sentinel Oncology receives Innovate UK grant to develop new drugs for the treatment of glioblastoma multiforme Read More
Press Release James Cotton 18/07/2017 Press Release James Cotton 18/07/2017 Sentinel Oncology receive Innovate UK grant to study feasibility of drug in the treatment of Alzheimer's disease Read More
Press Release James Cotton 02/05/2016 Press Release James Cotton 02/05/2016 Sentinel Oncology and NMI TT Pharmaservices awarded Eurostars grant for development of a novel biomarker for the treatment of Fragile X Syndrome Read More
Press Release James Cotton 25/03/2015 Press Release James Cotton 25/03/2015 Sentinel Oncology announce recent grant award from Innovate UK Read More
Press Release James Cotton 22/04/2014 Press Release James Cotton 22/04/2014 Sentinel Oncology and Oncothyreon Collaborate to Develop and Commercialise Small Molecule Chk1 Inhibitors Read More
